Delving into the Latest Updates on Sulfamethoxazole/Trimethoprim with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bactramin Combination Granule, Baktar Combination Granules, co-trimoxazole

+ [25]

Target

DHPS

Action

inhibitors

Mechanism

DHPS inhibitors(Dihydropteroate synthase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOtorhinolaryngologic Diseases+ [3]

Active Indication

Infectious DiseasesEnteritisRespiratory Diseases+ [14]

Inactive Indication

HIV SeropositivityMalariaPregnancy Complications, Infectious

Originator Organization

Roche Holdings, Inc.

Active Organization

Tsuruhara Pharmaceutical Co. Ltd.Monarch Pharmaceuticals LLCTaiyo Pharma Co., Ltd.

+ [4]

Inactive Organization

Institut Pasteur

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (30 Jul 1973),

Acute otitis mediaBronchitis, ChronicDysentery, Bacillary+ [3]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H29N7O6S

InChIKeyWZRJTRPJURQBRM-UHFFFAOYSA-N

CAS Registry8064-90-2

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.
The main questions this study is asking are:
* Does TMP-SMX lower the number of UTIs in the first year after transplant?
* What side effects or problems do participants have while taking TMP-SMX?
Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.
Participants will:
* Take either TMP-SMX or a placebo pill by mouth every day for 6 months
* Have three visits to touch base with the study team about any issues
* Complete short monthly online surveys about any symptoms or side effects
* Share blood and urine test results from their regular transplant clinic visits

Start Date01 Nov 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07224997

/ Not yet recruitingPhase 2IIT

Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections

Official Title
Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial
Brief Summary
Acute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP/SMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP/SMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety/adverse events, and healthcare utilization through 180 days.
Detailed Description
Adults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP/SMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP/SMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.
Study Design
* Study Type: Interventional (Clinical Trial)
* Primary Purpose: Prevention
* Allocation: Randomized (1:1)
* Intervention Model: Parallel Assignment
* Masking: Double-blind (Participant, Outcomes Assessor)
* Estimated Enrollment: 60 patients per group
* Study Start Date: December 2025
* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)
* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)
Arms & Interventions
Experimental: TMP/SMX
* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours
* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours, for 90 days post-discharge.
* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F
Placebo Comparator: Placebo
* Intervention: Drug: Placebo (matching oral tablet)
* Dosing: Matching schedule for 90 days post-discharge.
Concomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.
Outcome Measures
Primary Outcome
• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and/or antimicrobial treatment initiation.
Secondary Outcomes
1. Time to first infection (days) within 90 days.
2. Infection-related hospitalization within 90 and 180 days.
3. All-cause mortality at 90 and 180 days.
4. Emergency department visits or unplanned readmissions within 180 days.
5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg/dL, hyperkalemia ≥5.5 mmol/L) through 180 days.
6. C. difficile infection within 180 days.
7. Recurrent AKI (KDIGO criteria) within 180 days.
8. Medication adherence (pill counts and/or self-report) over 90 days.
9. Major adverse kidney events over 90 days.
Eligibility Criteria
Inclusion Criteria
* Age ≥18 years.
* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.
* Planned discharge to community/rehabilitation with capacity for follow-up.
* Ability to provide informed consent.
Exclusion Criteria
* Known allergy to sulfonamides or TMP/SMX.
* Pregnancy or breastfeeding.
* Severe hepatic disease (e.g., Child-Pugh C).
* Severe cytopenia (e.g., ANC <1.0×10⁹/L or platelets <50×10⁹/L).
* Baseline hyperkalemia (>5.5 mmol/L) not correctable prior to randomization.
* Concomitant medications with high-risk interactions not amenable to dose/monitoring (per protocol).
* Current systemic antimicrobial therapy planned for >14 days after discharge (prophylaxis not indicated).
* Inability to adhere to study procedures or follow-up.
Contacts/Locations
* Lead Sponsor / Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología
* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609
* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.
Ethics and Oversight
* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.
* IRB/Ethics approval: Comité de etica en investigacion, Protocol CEI 214/25, Approval : October 16, 2025.
* Written informed consent obtained from all participants prior to any study procedures.
* Data

Start Date01 Dec 2025

Sponsor / Collaborator

Hospital Civil de Guadalajara

CTIS2024-516232-10-00

/ Not yet recruitingPhase 4IIT

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date01 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

100 Clinical Results associated with Sulfamethoxazole/Trimethoprim

Login to view more data

100 Translational Medicine associated with Sulfamethoxazole/Trimethoprim

Login to view more data

100 Patents (Medical) associated with Sulfamethoxazole/Trimethoprim

Login to view more data

23,934

Literatures (Medical) associated with Sulfamethoxazole/Trimethoprim

31 Dec 2025·ANNALS OF MEDICINE

Clinical and laboratory indicators predicting coagulase-negative staphylococci as a cause of bloodstream infection among children below five years of age admitted at a tertiary hospital in Dar es Salaam, Tanzania

Article

Author: Nkinda, Lilian ; Kibwana, Upendo ; Kasubi, Mabula ; Majigo, Mtebe ; Mkopi, Namala ; Charles, Anjela ; Masoud, Salim ; Manyahi, Joel ; Joachim, Agricola ; Juma, Petro

BACKGROUND:

Coagulase-negative staphylococci (CoNS) are the most commonly isolated bacteria from blood cultures and the most considered contaminants. We conducted a study to assess clinical and laboratory indicators predicting CoNS as a cause of bloodstream infections using two sets of blood cultures among under-five children in Dar es Salaam, Tanzania. In addition, we determined the antimicrobial susceptibility patterns of CoNS.

MATERIALS AND METHODS:

This cross-sectional study involved 246 children clinically diagnosed with bloodstream infections admitted to a tertiary hospital . Two sets of blood cultures were collected per patient. Blood samples were tested for microbial growth and antimicrobial susceptibility. Indicators independently predicting CoNS as a cause of bloodstream infection were calculated by binary logistic regression analysis, receiver operating characteristic (ROC) curve analysis to assess the diagnostic performance of predictors. A p-value <0.05 at 95% confidence intervals was considered significant.

RESULTS:

Of 246 patients, 100(40.7%) were positive blood cultures. CoNS were the most prevalent, isolated in 51(51.0%) blood cultures. Of 51 blood cultures with CoNS, 40(78.4%) were isolated in both blood culture bottles of a set and were regarded as causative of bloodstream infection,of this 34(85.0%) were methicillin resistance CoNS. Multivariate analysis identified tachycardia (aOR = 14.69, 95%CI 1.36-158.42, p = 0.027) and in situ intravenous cannulation (aOR = 66.75, 95%CI 3.61-1234.40, p = 0.005) as significant predictors of CoNS bloodstream infection, with a prediction score of 94.1%. The ROC curve analysis demonstrated tachycardia and in situ intravenous cannulation had AUC > 0.7 (p < 0.05). The CoNS were frequently resistant to penicillin (97.5%), erythromycin (82.5%), and trimethoprim-sulfamethoxazole (77.5%).

CONCLUSIONS:

CoNS remains the most common bacteria causing bloodstream infections. In situ intravenous cannulation and tachycardia were potential clinical indicators in improving early diagnosis of CoNS as a cause of bloodstream infections and guiding timely treatment decisions. High antimicrobial resistance observed necessitating strengthening of antimicrobial stewardship.

31 Dec 2025·Gut Microbes Reports

Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant Salmonella enterica

Author: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony

Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.

01 Dec 2025·MICROBIOLOGICAL RESEARCH

Combined use of vitamin C and antifolates induces cuproptosis-like bacterial death

Article

Author: Li, Kun ; Deng, Jiaoyu ; Yu, Jifang ; Si, Lizhen ; Yang, Junmei ; Cai, Jinjing ; Gu, Jing ; Wen, Mi ; Liu, Zixiang

Combined use of antimicrobial agents is a key strategy to combat antimicrobial resistance. After several decades of approval, clinical application of the classical combination co-trimoxazole has gradually become limited, mainly due to the prevalence of resistance. Vitamin C is a natural antimicrobial and redox agent. While sporadic studies suggest vitamin C might synergize with antimicrobial drugs, results have been inconsistent and the underlying mechanisms are unclear. Here we show that vitamin C increased bacterial sensitivity to antifolates and protein synthesis inhibitors through different mechanisms, including altered para-aminobenzoic acid and branched chain amino acids biosynthesis. However, vitamin C enhanced the bactericidal effect of those drugs through a common mechanism-inducing cuproptosis-like bacterial death. Treating bacteria with vitamin C caused a transient accumulation of cuprous ions, which could be buffered by the bacterial copper homeostasis systems. However, coadministration of those drugs undermined the bacterial copper homeostasis systems and led to a buildup of cuprous ion, ultimately causing cuproptosis-like bacterial death as characterized by aggregation of lipoylated proteins. The accumulated cuprous ions further released ferrous ions, which stimulated a surge in reactive oxygen species and exacerbated bacterial death by generating excessive DNA damage. This study provides a novel rationale for the combined use of vitamin C and existing antimicrobial drugs.

19

News (Medical) associated with Sulfamethoxazole/Trimethoprim

08 Jul 2025

·pharma.economictimes.indiatimes.com

NITI Aayog Meet: Small Drugmakers Push Back on NPPA Price Caps, Seek Financial Assistance

New Delhi: Amid rising concerns over the growing incidence of substandard drugs produced by MSME units in India, small drugmakers have argued that unsustainable price caps and insufficient financial support are undermining their ability to maintain quality and address other compliance issues. At a high-level meeting with NITI Aayog—attended by Dr. V.K. Paul, the Drug Controller General of India (DCGI), and other key officials— CIPI Chairman RK Jain concerned that the pricing regulations imposed by the National Pharmaceutical Pricing Authority (NPPA) have severely affected the margins of small manufacturers and has pushed many quality drugs out of the domestic market. “Unsustainable pricing has pushed many quality drugs out of the domestic market,” he said. The representative also urged the government to provide financial assistance to help MSME pharmaceutical firms build infrastructure for stability studies and reduce the incidence of Not of Standard Quality (NSQ) drugs. Citing the example of co-trimoxazole, he highlighted that the ceiling price set by the National Pharmaceutical Pricing Authority (NPPA) has compelled small manufacturers to discontinue its production. Co-trimoxazole, an antibiotic indicated to treat bacterial infections was added to the national list of essential medicines (NLEM) in 2022, that resulted in the average reduction of around 16 per cent. Currently, the ceiling price for co-trimoxazole oral liquid (5 ml suspension) is capped at ₹0.35 per ml, while the tablet form is priced at ₹0.9 and ₹2.3 for higher dosage strength. Under Schedule I of the Drug Price Control Order (DPCO), 2013, the NPPA regulates both bulk drugs and formulations listed in the NLEM by fixing ceiling and retail prices to ensure affordability. Marketers are allowed to raise prices in line with inflation, based on the Price Differential Index prepared by the Office of the Economic Adviser (OEA), Ministry of Commerce and Industry. Meanwhile, over the dealy in compliance with the revised schedule M norms, representatives from other lobby groups such as Laghu Udyog Bharati, FOPE, IDMA and several others presented that, “gap analysis and detailed data requirements create hindrances in filing for entitlement for many companies, as many changes occur during development.” “MSME below ₹50 crores needed hand-holding and further extension in Revised Schedule M, as well as simplification of DOP-derived RPTUAS as per Revised Schedule M or WHO Good Manufacturing Practices (GMP),” the representatives noted. The PTUAS (Pharmaceutical Technology Upgradation Assistance Scheme) is a credit-linked initiative offering up to ₹1 crore in financial aid for MSME pharma units aiming to upgrade their facilities to WHO-GMP or Schedule M standards. Besides this, the industry representatives has also called for incentivising the compliance process by offering rewarding with ₹50 lakhs to ₹2 crores to companies that successfully obtain license through joint inspections of CDSCO and state regulatory bodies. Small drugmakers are those entities who have an annual turnover of or less than ₹250 crore and of the country’s total poll of 10,500 manufacturers around 8,500 fall under the MSME category. However, according to the Ministry of Health, only 2,000 of these units are WHO-GMP certified—highlighting the urgent need for targeted policy support, infrastructure upgradation, and regulatory collaboration to ensure quality manufacturing at scale. By Abhijeet Singh ,

NDA

24 Jan 2025

·pharma.economictimes.indiatimes.com

Paracetamol among 135 drugs fails CDSCO quality test

New Delhi: During its monthly review undertaken to monitor and ensure the quality of drugs manufactured in the country, the apex drug regulator CDSCO has identified 135 drug batches including Paracetamol, Vitamin D3 supplements, anti-diabetic pills, high blood pressure etc. as ‘Not of Standard Quality’ (NSQ). Paracetamol Tab IP 500 mg which failed to meet the quality standards was picked by the Drugs Testing Laboratory Thiruvananthapuram and is manufactured by Kerala Medical Services Corporation Ltd. As per the regulators' alert the identified sample, “fails the test ‘Dissolution’ as per IP ( Indian Pharmacopoeia ).” Another Paracetamol Tablet with a dosage strength of 650 mg was manufactured by VivekPharmachem and failed to meet the quality standards when tested by the Karnataka state laboratory. It is flagged as NSQ. Paracetamol is indicated for headache, period pain and cold or flu symptoms and is easily available as over-the-counter medication. In the December drug alert, the Central Drugs Standards Control Organisation (CDSCO) declared 135 drug samples as NSQ. Among these 51’ samples were picked by the regulator’s central drug laboratories while the state laboratories identified the remaining ‘84’ NSQ samples. In the central list, the drugs and formulations which have been identified as NSQ include Paracetamol Paediatric Oral Suspension manufactured by ION Healthcare; Doxycycline capsules by Hindustan Antibiotics; Glimepiride Tablets by Life Max Cancer Laboratories; Co - trimoxazole by Omega Pharma among 47 others. The State NSQ list comprises Metformin Hydrochloride tablets manufactured by Cipla Ltd; Divalproex Extended Release tablets of Biodeal Pharmaceuticals; and Betahistine Dihydrochloride Tablets by CMG BIOTECH among 81 others. The majority of the drug batches tested by the regulator were manufactured in 2023, 2024 and were set to expire in the next two years depending upon the date of their manufacturing. As per the Health Ministry, “previous month, this month’s NSQ reporting from states has further increased showing increased participation of States in reporting NSQs to the central database.” “Increased reporting of NSQs/Spurious identifications from states to central database will further help in improving availability of quality medicines in the country and beyond,” the ministry added. The drugs that fail to meet the quality standards or specifications are listed as Not of Standard Quality (NSQ) drugs where the term ‘standards of quality’ is defined under Section 16 (1) (a) of Drugs & Cosmetics Act, 1940. By Online Bureau ,

NDA

04 Nov 2024

·www.drugs.com

Nitrofurantoin, Cranberry Products May Cut UTI Episodes in Children

MONDAY, Nov. 4, 2024 -- For children with a history of recurrent urinary tract infection (RUTI), nitrofurantoin and cranberry products may reduce the incidence of symptomatic UTI episodes, according to a review published online Nov. 4 in Pediatrics . Nikolaos Gkiourtzis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review of randomized controlled trials comparing prophylaxis options for the prevention of UTI and kidney scarring in children with a history of RUTI. A total of 3,335 participants from 23 studies were included in the meta-analysis. The researchers found that cranberry products (compared with the control group) and nitrofurantoin (compared with the control, trimethoprim-sulfamethoxazole, or trimethoprim groups) led to lower odds of symptomatic UTI episodes during prophylaxis. Compared with all available documented interventions, nitrofurantoin appeared to be the best option for reduction in the incidence of UTI. None of the prophylaxis options showed a reduction in kidney scarring. "Future studies with optimal methodology, studying nonantibiotic prophylaxis options, focusing on children with RUTI, and the risk for kidney scarring are needed to draw further conclusions," the authors write. Abstract/Full Text Editorial (subscription or payment may be required) Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Sulfamethoxazole/Trimethoprim

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sulfamethoxazole/Trimethoprim	J01EE01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	United States	Pharmaceutical Associates, Inc.	07 Jan 1983
Enteritis	Japan	Tsuruhara Pharmaceutical Co. Ltd.	24 Mar 1981
Respiratory Diseases	Japan	Tsuruhara Pharmaceutical Co. Ltd.	24 Mar 1981
Bacterial Infections	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Cystitis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Cystitis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Paratyphoid Fever	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pneumonia	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Pneumonia	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Secondary infection	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Acute otitis media	United States	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Acute otitis media	United States	Monarch Pharmaceuticals LLC	30 Jul 1973
Bronchitis, Chronic	United States	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Bronchitis, Chronic	United States	Monarch Pharmaceuticals LLC	30 Jul 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Seropositivity	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013
Malaria	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013
Pregnancy Complications, Infectious	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Literature Manual	Phase 2/3	Whipple Disease	64	oral doxycycline +hydroxychloroquine	racmfiuonp(dmycwwcqjm) = xekwnxhrqw izfosqzcon (eehrrkbfjh ) View more	Non-inferior	17 Feb 2025
				intravenous ceftriaxone+oral trimethoprim-sulfamethoxazole	racmfiuonp(dmycwwcqjm) = cuhzgpvaui izfosqzcon (eehrrkbfjh ) View more
NCT05418777 (CTgov)	Phase 1/2	Pulmonary Disease, Chronic Obstructive	1	Trimethoprim Sulfamethoxazole (TMP-SMX)	udyihwtjdl(uywriujmcn) = dyhqsodjrn ugfdtykslr (ngswuksyom, 0) View more	-	29 Nov 2023
				Placebo (Placebo)	dhvcuqxtae(vfteoxasxa) = uajbatwyof gctkolbbth (rqvellkvqa, uhrsgaympo - sgztkgdxjg) View more
EULAR2022	Not Applicable	Rheumatic Diseases	438	Patients with AEs of SMX/TMP	vwijhupftc(cxmiznqzop) = pcjxrrhqjw ytnkhfjkmc (pwhetbyfis ) View more	Positive	01 Jun 2022
				Patients without AEs of SMX/TMP	vwijhupftc(cxmiznqzop) = eagnzikfos ytnkhfjkmc (pwhetbyfis ) View more
NCT03431168 (PREMISE, CTgov)	Phase 2	HIV Infections \| Malaria	308	TMPS+Azithromycin (Azithromycin/TMPS)	izzbrupywx = jidngumehb kklvgqywwx (zfnjdkybyt, dmzetgrrlb - psmigqzwxd) View more	-	04 May 2022
				Placebo/TMPS (Placebo/TMPS)	izzbrupywx = vvbpgtmsub kklvgqywwx (zfnjdkybyt, cdjielmkzd - buglngwahb) View more
UEGW2021	Not Applicable	Inflammatory Bowel Diseases	-	TMP/SMX prophylaxis	fcruyzeudo(jbmdmxawcb) = snevhomvnk ewnieyzbzw (rbvbwmyfow )	-	02 Oct 2021
				No TMP/SMX prophylaxis	fcruyzeudo(jbmdmxawcb) = apzepjrgyo ewnieyzbzw (rbvbwmyfow )
ATS2021	Not Applicable	COVID-19 C Reactive protein	142	Co-Trimoxazole	sjtkdkdzae(nssebeogns) = mbafccywxy gjeuvaldtn (mlrqooulta, 39)	Positive	03 May 2021
NCT01650558 (Pubmed \| Clin Infect Dis)	Not Applicable	-	1,499	Continue daily co-trimoxazole	vaeovhxnkg(glkcxotppp) = vtbkhmykna lydjrbeuud (dkpcteulti )	-	21 Mar 2021
				Discontinue daily co-trimoxazole and begin weekly chloroquine	vaeovhxnkg(glkcxotppp) = ijgacjlzuq lydjrbeuud (dkpcteulti )
NCT02759120 (CleanUP-IPF, CTgov)	Phase 3	Idiopathic Pulmonary Fibrosis	513	No Intervention: Standard of Care	qppzkwytfe = mlyleamdvs uyftjyvtzw (skjxwqolfz, dbdimjnvse - ewgfemoqbw) View more	-	03 Mar 2021
NCT00867789 (CTgov)	Not Applicable	Abscess	140	Trimethoprim-sulfamethoxazole (Trimethoprim-sulfamethaxazole)	fxufqvragz = bwqvdsjdjq dkylgqhvbq (ulyvvikafj, hcqysztlfl - mufvvulpgy) View more	-	26 Jan 2021
				sugar pill (Sugar Pill)	fxufqvragz = iccksnvfng dkylgqhvbq (ulyvvikafj, qmrbhpxzvl - qjylcvalsh) View more
NCT02773407 (Pubmed \| Clin Infect Dis)	Phase 3	Fever	326	Trimethoprim-sulfamethoxazole (SXT)	sfavbcrssn(nogltpxibg) = epzdktbdho lgnretpqdr (alpqmmitjq, 2.6 - 3.3)	Positive	29 Sep 2020
				Azithromycin	sfavbcrssn(nogltpxibg) = kojfzzdcxu lgnretpqdr (alpqmmitjq, 1.6 - 3.2)